Moreover, high neutrophil count prior to treatment correlates with positive initial response to the vascular endothelial growth factor A (VEGF-A) antibody bevacizumab, and enhanced neutrophil infiltration into tumor tissue is associated with acquired resistance [9]. This evidence concerns the gene VEGFA and neoplasm.